Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial
Paul R. Kalra, John G.F. Cleland, Mark C. Petrie, Elizabeth A. Thomson, Philip A. Kalra, Iain B. Squire, Fozia Z. Ahmed, Abdallah Al-Mohammad, Peter J. Cowburn, Paul W.X. Foley, Fraser J. Graham, Alan G. Japp, Rebecca E. Lane, Ninian N. Lang, Andrew J. Ludman, Iain C. Macdougall, Pierpaolo Pellicori, Robin Ray, Michele Robertson, Alison SeedIan Ford (Lead / Corresponding author), IRONMAN Study Group
Dive into the research topics of 'Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial'. Together they form a unique fingerprint.